Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Effectiveness of Pressure Lowering Treatment in Ocular Hypertension and Manifest Open-angle Glaucoma: A Meta-analysis of Randomized Controlled Trials
Maier P.1, Funk J.1, Schwarzer G. 2, Antes G. 2, Falck-Ytter Y.2
1Universistätsaugenklinik Freiburg; 2Deutsches Cochrane Zentrum, Universitätsklinik Freiburg, Institut für Med. Biometrie und Med. Informatik, Freiburg
Purpose: Ocular pressure-lowering treatments are widely used in glaucoma prevention, despite the fact that most people with ocular hypertension (OHT) alone, will not develop glaucoma. Interestingly, previous meta-analysis in OHT could not demonstrate a significant treatment effect. Additionally, treatment effectiveness in manifest glaucoma had not been shown in well-designed randomized controlled trials. We reassessed the effectiveness of pressure-lowering treatment in ocular hypertension and open-angle glaucoma.
Method: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and other databases were searched for relevant trials. Eligible studies were randomized controlled trials with a concurrent untreated control group and information about the onset of visual field deteriorations and definite glaucomatous disc changes.
Results: Meta-analysis of 4 adequate trials on treatment of ocular hypertension showed a significant preventive effect on progression to glaucoma (hazard ratio (HR): 0.55, 95% confidence interval (CI): 0.35 - 0.87, p=0.01). In manifest glaucoma with and without intraocular pressure elevation, only